Gynecologic Malignancies - Novel Phase II Agents

Wadler, Scott H.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01CA063422-03
• Application #: 2105259
• Study Section: Special Emphasis Panel (SRC (62))
• Project Start: 1994-06-03
• Project End: 1998-03-31
• Budget Start: 1996-04-01
• Budget End: 1997-03-31
• Support Year: 3
• Fiscal Year: 1996

Institution

• Name: Montefiore Medical Center (Bronx, NY)
• City: New York
• State: NY
• Country: United States
• Zip Code: 10467

Publications

Einstein, Mark H; Kadish, Anna S; Burk, Robert D et al. (2007) Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106:453-60

Dabon-Almirante, C L; Damle, S; Wadler, S et al. (1999) Related case report: in vivo suppression of thyrotropin by 9-cis retinoic acid. Cancer J Sci Am 5:171-3

Wadler, S; Schwartz, E L; Anderson, P et al. (1999) Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group. Cancer J Sci Am 5:165-70

Challagalla, J D; Smith, R; Mitnick, R et al. (1999) Carcinoma of the uterine cervix metastatic to behind the zygomatic arch: a case report. Am J Otolaryngol 20:195-7

Hochster, H; Wadler, S; Runowicz, C et al. (1999) Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 17:2553-61

Wadler, S; Schwartz, E L; Haynes, H et al. (1997) All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Cancer 79:1574-80